Baidu
map

JAHA:成年先心病的死因和并发症研究

2020-07-14 MedSci原创 MedSci原创

目前对成人先天性心脏病(CHD)死亡经验知之甚少。本研究的目的是评估美国当代人群中成年先心病患者的死亡年龄、心血管并发症的存在以及最常见的死因。

目前对成人先天性心脏病(CHD)死亡经验知之甚少。本研究的目的是评估美国当代人群中成年先心病患者的死亡年龄、血管并发症的存在以及最常见的死因。

本研究纳入分析了629名死亡年龄≥20岁的成年先心病患者,死亡时的平均年龄是64.2岁。严重先心病(n=157,25%)、分流(n=202,32%)和瓣膜病变(n=174,28%)的患者的中位死亡年龄分别为46.0岁、65.0岁和73.3岁。严重先心病患者最常见的死因是心源性死亡。恶性肿瘤和缺血性心脏病是成人非严重先心病最常见的死亡原因。高血压和高血脂是成年先心病患者常见的并发症。

研究结果显示,对于成年先心病患者,最常见的潜在死亡原因因病变严重程度不同而不同。那些有严重病变的人通常死于潜在的先心病,而那些患有非严重疾病的人则更多地死于非先心病。

原始出处:

Sarah A et al.Causes of Death and Cardiovascular Comorbidities in Adults With Congenital Heart Disease.JAHA.2020 July.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1758257, encodeId=d6101e582579f, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Oct 06 20:08:04 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807284, encodeId=c4bb80e2846e, content=♚♚♚, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2ab2486579, createdName=1246cdbam15暂无昵称, createdTime=Mon Aug 10 14:59:09 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268289, encodeId=35991268289cf, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Jul 16 08:08:04 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311505, encodeId=b84a13115050a, content=<a href='/topic/show?id=a12628e0852' target=_blank style='color:#2F92EE;'>#先心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28708, encryptionId=a12628e0852, topicName=先心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Thu Jul 16 08:08:04 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802781, encodeId=e25f802e81af, content=这样本量, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04f25400453, createdName=ms2000001909635546, createdTime=Tue Jul 14 18:40:17 CST 2020, time=2020-07-14, status=1, ipAttribution=)]
    2020-10-06 丁鹏鹏
  2. [GetPortalCommentsPageByObjectIdResponse(id=1758257, encodeId=d6101e582579f, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Oct 06 20:08:04 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807284, encodeId=c4bb80e2846e, content=♚♚♚, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2ab2486579, createdName=1246cdbam15暂无昵称, createdTime=Mon Aug 10 14:59:09 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268289, encodeId=35991268289cf, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Jul 16 08:08:04 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311505, encodeId=b84a13115050a, content=<a href='/topic/show?id=a12628e0852' target=_blank style='color:#2F92EE;'>#先心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28708, encryptionId=a12628e0852, topicName=先心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Thu Jul 16 08:08:04 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802781, encodeId=e25f802e81af, content=这样本量, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04f25400453, createdName=ms2000001909635546, createdTime=Tue Jul 14 18:40:17 CST 2020, time=2020-07-14, status=1, ipAttribution=)]
    2020-08-10 1246cdbam15暂无昵称

    ♚♚♚

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1758257, encodeId=d6101e582579f, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Oct 06 20:08:04 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807284, encodeId=c4bb80e2846e, content=♚♚♚, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2ab2486579, createdName=1246cdbam15暂无昵称, createdTime=Mon Aug 10 14:59:09 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268289, encodeId=35991268289cf, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Jul 16 08:08:04 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311505, encodeId=b84a13115050a, content=<a href='/topic/show?id=a12628e0852' target=_blank style='color:#2F92EE;'>#先心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28708, encryptionId=a12628e0852, topicName=先心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Thu Jul 16 08:08:04 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802781, encodeId=e25f802e81af, content=这样本量, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04f25400453, createdName=ms2000001909635546, createdTime=Tue Jul 14 18:40:17 CST 2020, time=2020-07-14, status=1, ipAttribution=)]
    2020-07-16 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=1758257, encodeId=d6101e582579f, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Oct 06 20:08:04 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807284, encodeId=c4bb80e2846e, content=♚♚♚, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2ab2486579, createdName=1246cdbam15暂无昵称, createdTime=Mon Aug 10 14:59:09 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268289, encodeId=35991268289cf, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Jul 16 08:08:04 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311505, encodeId=b84a13115050a, content=<a href='/topic/show?id=a12628e0852' target=_blank style='color:#2F92EE;'>#先心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28708, encryptionId=a12628e0852, topicName=先心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Thu Jul 16 08:08:04 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802781, encodeId=e25f802e81af, content=这样本量, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04f25400453, createdName=ms2000001909635546, createdTime=Tue Jul 14 18:40:17 CST 2020, time=2020-07-14, status=1, ipAttribution=)]
    2020-07-16 ssnine
  5. [GetPortalCommentsPageByObjectIdResponse(id=1758257, encodeId=d6101e582579f, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Oct 06 20:08:04 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807284, encodeId=c4bb80e2846e, content=♚♚♚, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2ab2486579, createdName=1246cdbam15暂无昵称, createdTime=Mon Aug 10 14:59:09 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268289, encodeId=35991268289cf, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Jul 16 08:08:04 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311505, encodeId=b84a13115050a, content=<a href='/topic/show?id=a12628e0852' target=_blank style='color:#2F92EE;'>#先心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28708, encryptionId=a12628e0852, topicName=先心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Thu Jul 16 08:08:04 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802781, encodeId=e25f802e81af, content=这样本量, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04f25400453, createdName=ms2000001909635546, createdTime=Tue Jul 14 18:40:17 CST 2020, time=2020-07-14, status=1, ipAttribution=)]
    2020-07-14 ms2000001909635546

    这样本量

    0

相关资讯

JACC:无聚合物和耐用型聚合物药物洗脱支架的远期预后比较

在随机临床试验中,对使用药物洗脱支架(DES)治疗的冠心病患者进行长期长期随访后的结果数据很少。本研究的目的旨在评估ISAR-TEST-5临床试验中患者的10年随访结果。

JACC:阿利昔单抗对纯合子家族性高胆固醇血症患者的疗效研究

纯合子家族性高胆固醇血症(HoFH)的特点是低密度脂蛋白胆固醇(LDL-C)水平异常升高和早期动脉粥样硬化性心血管疾病。本研究旨在评估前蛋白转化酶枯草杆菌素9抑制剂阿利昔单抗对成人HoFH患者低密度脂

JACC:出院后出血与急性心梗患者死亡率相关

在未经皮冠状动脉介入治疗(PCI)的急性冠脉综合征(ACS)患者中,出院后出血的长期预后影响尚不清楚。本研究的目的是根据治疗策略(PCI或非PCI)评估ACS患者出院后出血与随后死亡率之间的关系。

JACC:美国成年先心病患者的特征评估

在美国有超过100万名先心病成年人,本研究目的旨在评估年龄在20至64岁的先心病患者的人口统计学、并发症和医疗保健使用情况。

JACC:PRKAG2综合征的临床特征和自然病程研究

PRKAG2基因变异可导致一种以心肌病、传导疾病和心室预激为特征的综合征,到目前为止,只有少数病例报告,对该病的自然史了解甚少。本研究的目的是在一个大型多中心欧洲队列中描述PRKAG2变异的表型和自然

盘点:JACC七月第2期研究一览

1. 阿利昔单抗对纯合子家族性高胆固醇血症患者的疗效研究

Baidu
map
Baidu
map
Baidu
map